Lipotropic compounds support hepatic fat metabolism by acting as methyl donors and phospholipid precursors
When to Continue Your GLP-1 Medication For mild to moderate colds and flu, most people can safely continue their regular GLP-1 medication schedule
T-cell cancer after CAR T-cell therapy
Your plan is tailored based on your medical history, metabolic profile, lifestyle, and personal goals
SGLT2 inhibitors - the new standard of care for cardiovascular, renal and metabolic protection in type 2 diabetes: A narrative review
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodiumglucose cotransporter-2 inhibitors (SGLT2is) both provide cardiovascular benefit, although their clinical profiles differ as SGLT2 inhibitors have shown greater reductions in HF hospitalization, whereas GLP-1 receptor agonists appear particularly effective in reducing atherosclerotic events such as stroke [5, 6]